TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
EBS

Emergent Biosolutions Inc

Healthcare · Drug Manufacturers - Specialty & Generic

7.00$ +4.0% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Income Statement

Emergent Biosolutions Inc (EBS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Revenue" came in at 743 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement EBS
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
404 489 489 561 782 1,106 1,577 1,774 1,118 1,049 1,044 743
207 217 244 277 462 623 714 980 645 689 668 392
198 272 245 284 320 483 863 793 473 360 375 351
105 119 107 97 143 226 238 235 188 111 71 54
123 148 144 143 203 274 303 348 340 373 308 186
109 131 139 159 231 369 425 452 643 1,086 484 240
89 142 106 124 90 114 439 341 -170 -726 -109 110
8.2 6.5 7.6 6.6 9.9 38 31 35 37 88 71 59
84 136 99 119 82 77 412 303 -219 -731 -143 83
30 44 37 36 19 23 106 84 -7.4 29 48 30
37 63 52 83 63 55 306 220 -212 -761 -191 53
122 187 133 175 155 259 609 504 16 -47 53 240

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?